Association of Levels of Mannose-Binding Lectin and the \textit{MBL2} Gene with Type 2 Diabetes and Diabetic Nephropathy

Nana Zhang\textsuperscript{1,9}, Maoqiang Zhuang\textsuperscript{1,9}, Aixia Ma\textsuperscript{1}, Guochang Wang\textsuperscript{1}, Ping Cheng\textsuperscript{1}, Yajun Yang\textsuperscript{2,3}, Xiaofeng Wang\textsuperscript{2,3}, Juan Zhang\textsuperscript{3}, Xingdong Chen\textsuperscript{2,3}, Ming Lu\textsuperscript{1,2,3*}

\textsuperscript{1} Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, Shandong, P. R. China, \textsuperscript{2} MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, P. R. China, \textsuperscript{3} CMC Institute of Health Sciences, Taizhou, Jiangsu, P. R. China

Abstract

\textbf{Objective}: To investigate the association of Mannose-binding lectin (MBL) and the \textit{MBL2} gene with type 2 diabetes and diabetic nephropathy and the influence of \textit{MBL2} polymorphisms on serum MBL levels.

\textbf{Methods}: The study population included 675 type 2 diabetic patients with or without nephropathy and 855 normoglycemic controls. The single nucleotide polymorphisms (SNPs) of rs1800450, rs1800451, and rs11003125 of the \textit{MBL2} gene were determined by the Multiplex Snapshot method. Serum MBL levels were measured by enzyme-linked immune sorbent assay.

\textbf{Results}: Rs1800450 and rs11003125 SNPs demonstrated strong linkage disequilibrium in the study population (\(\chi^2 = 0.97\)). The haplotype constructed from the G allele of rs1800450 and the C allele of rs11003125 increased the risk for type 2 diabetes (OR = 1.2, 95\% CI = 1.1–1.4, \(P = 0.01\)). For rs1800450, GG and GA genotypes were associated with type 2 diabetes (\(P = 0.02\), 0.01, respectively). For rs11003125, the GC genotype frequency was significantly different between patients and controls (18.1\% vs. 24.9\%, \(P = 0.001\)). Analyses of genotypes and allele frequency distributions among patients with normal UAE, microalbuminuria, and macroalbuminuria showed that there was no obvious evidence of association between the \textit{MBL2} gene and diabetic nephropathy. Subjects with the GG genotype of rs1800450 and the CC genotype of rs11003125 had much higher serum MBL levels.

\textbf{Conclusions}: The rs1800450 and rs11003125 SNPs of the \textit{MBL2} gene have strong linkage disequilibrium and are associated with type 2 diabetes in the North Chinese Han population. No association was observed between the \textit{MBL2} gene and diabetic nephropathy. Subjects with the GG genotype of rs1800450 and the CC genotype of rs11003125 had much higher serum MBL levels. An association between elevated serum MBL and diabetic nephropathy was also observed.

Citation: Zhang N, Zhuang M, Ma A, Wang G, Cheng P, et al. (2013) Association of Levels of Mannose-Binding Lectin and the \textit{MBL2} Gene with Type 2 Diabetes and Diabetic Nephropathy. PLoS ONE 8(12): e83059. doi:10.1371/journal.pone.0083059

Editor: Michael Costigan, Boston Children’s Hospital and Harvard Medical School, United States of America

Received October 30, 2013; Accepted December 20, 2013

Copyright: © 2013 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a grant from NSFC (30973595) and a grant from SDSTC (BS2009SW038). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

\* E-mail: lvming@hdu.edu.cn

\textsuperscript{9} These authors contributed equally to this work.

Introduction

Epidemiological statistics showed that the age-standardized prevalence of diabetes (which included both previously diagnosed and undiagnosed diabetes) and prediabetes were 9.7\% and 15.5\% among Chinese adults, respectively, in 2008 [1]. The main hazard of diabetes comes from its complications. Among the complications, diabetic nephropathy is a common and devastating microvascular complication and its pathogenesis is still poorly understood [2], although complement activation and inflammation have been suggested to play essential roles in the pathogenesis of diabetes and diabetic vascular lesions [3–5].

Mannose-binding lectin (MBL, also known as mannan-binding lectin) is a C-type lectin secreted by the liver and is a component of the innate immune defense system [4]. MBL deficiency is associated with autoimmune, inflammatory, infectious, and vascular disease. Upon binding to specific carbohydrate structures, MBL activates the third pathway of complement (the lectin pathway) and aggravates inflammation [6]. Serum MBL levels are significantly elevated in patients with type 1 diabetes [3,4], and even higher in those patients with microvascular and macrovascular complications [7,8]. The median serum MBL level in healthy Caucasians is 800–1000 ng/ml [9,10], but MBL levels vary widely from person to person mainly because of frequently occurring polymorphisms within \textit{MBL2}, as well as in the promoter region of the \textit{MBL2} gene on chromosome 10. Three non-synonymous SNPs in exon1 named alleles B (G54D/rs1800450), C (G57E/rs1800451), and D (R52C/rs5030737) considerably decrease serum MBL levels due to incorrect assembly of the mature MBL protein [11].

PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e83059
The first aim of the present study was to investigate the association of MBL2 gene polymorphisms with type 2 diabetes and diabetic nephropathy in a Chinese Han population. The secondary aim was to validate the association between diabetic nephropathy and elevated MBL levels as previously studies have suggested. Third, the association between MBL2 polymorphisms and serum MBL levels was considered.

Subjects and Methods

Ethics Statement

This study was approved by the Ethics Committee of Qilu Hospital, Shandong University. All participants gave their written informed consent prior to participation.

Subjects

1530 subjects (675 type 2 diabetic patients and 855 controls) were recruited from Qilu Hospital of Shandong University, from March 2010 to October 2011. All study subjects were asked to complete an epidemiological survey by face to face interview (including their basic information, clinic indexes, and potential risk factors of diabetes). Subjects who reported a history of autoimmune diseases, inflammatory diseases, infectious diseases, type 1 diabetes or gestational diabetes were excluded. For normoglycemic controls, age- and sex-matched with patients,

Table 1. Basic characteristic of the study samples.

| Variables             | Type 2 diabetes | Controls | p   | Type 2 diabetes | Normal UAE | Microalbuminuria | Macroalbuminuria | p   |
|-----------------------|-----------------|----------|-----|-----------------|------------|------------------|-----------------|-----|
| N                     | 675             | 855      | 0.0001 | 260             | 378        | 37               |                 |     |
| Age (years)           | 62.0±12.7       | 64.3±10.3| <0.0001| 62.5±11.9       | 62.1±12.8  | 57.3±15.2        | 0.06            |     |
| Gender                |                 |          |      |                 |            |                  |                 |     |
| male                  | 334             | 390      |       | 142             | 171        | 21               |                 |     |
| female                | 341             | 465      | 0.13 | 118             | 207        | 16               | 0.04            |     |
| Smoking status        |                 |          |      |                 |            |                  |                 |     |
| Yes                   | 132             | 244      |       | 63              | 71         | 9                |                 |     |
| No                    | 543             | 611      | <0.0001| 197             | 307        | 28               | 0.23            |     |
| Drinking status       |                 |          |      |                 |            |                  |                 |     |
| Yes                   | 141             | 89       |       | 57              | 84         | 6                |                 |     |
| No                    | 534             | 766      | <0.0001| 203             | 294        | 31               | 0.70            |     |
| BM (kg/m²)            | 25.1±3.7        | 23.4±3.3 | <0.0001| 25.1±3.6        | 25.1±3.8   | 24.3±4.1         | 0.45            |     |
| WHR                   | 0.94±0.1        | 0.88±0.1 | <0.0001| 0.93±0.07       | 0.94±0.08  | 0.93±0.07        | 0.75            |     |
| SBP (mmHg)            | 137.4±20.3      | 129.1±16.8| <0.0001| 131.1±17.2      | 140.5±21.0 | 150.1±20.7       | <0.0001         |     |
| DBP (mmHg)            | 77.0±11.0       | 80.2±10.5| <0.0001| 74.8±9.9        | 77.9±11.3  | 82.2±11.4        | <0.0001         |     |
| TG (mmol/L)           | 1.8±1.6         | 1.5±1.0  | <0.0001| 1.81±1.88       | 1.79±1.36  | 2.09±1.94        | 0.56            |     |
| TC (mmol/L)           | 5.3±1.4         | 4.9±0.9  | <0.0001| 5.2±1.3         | 5.2±1.4    | 6.0±1.6          | 0.01            |     |
| FPG (mmol/L)          | 8.5±3.5         | 5.2±0.8  | <0.0001| 8.6±3.1         | 8.6±3.8    | 7.9±3.4          | 0.48            |     |
| Cr (µmol/L)           | 70(59–86)       | 68(54–83)| <0.0001| 66(58–76)       | 73(58–93)  | 100(79–218)      | <0.0001         |     |
| BUN (mmol/L)          | 5.6(4.5–7.1)    | 5.9(4.6–10.9)| <0.0001| 5.1(4.3–6.3)    | 5.7(4.5–8.0)| 8.9(6.5–15.8)    | <0.0001         |     |

MBL: body mass index; WHR: waist to hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; TC: total cholesterol; FPG: fasting plasma glucose; Cr: creatinine; BUN: blood urea nitrogen; UAE: urinary albumin excretion in 24 h.

Data are shown as mean ± SD, median (interquartile range) or N.

DOI:10.1371/journal.pone.0083059.t001
was excluded. The other three variants are localized in the promoter 1 (position –550, H/L variant (rs11003125) and –221, X/Y variant) and in the 5’ un-translated region (position +4, P/Q variant) of the MBL2 gene. Rs11003125 is the main variant in the promoter region of the MBL2 gene influencing serum MBL levels and is significantly associated with type 2 diabetes [2,11]. Finally, three SNPs (rs1800450, rs1800451, and rs11003125) were selected. The three SNPs were determined in 1530 subjects by the Multiplex Snapshot method. The genotyping completion rate was 98% for the first experiment. The samples that were not successfully genotyped may have been polluted or uncertain factors existed, so we did the experiment again and the ultimate genotyping completion rate was 99%. Genotyping accuracy was demonstrated by showing a greater than 99.8% overall concordance rate in 10 blinded duplicate samples. The primers of the three SNPs were designed with Primer 5.0 software (Table S1) and synthetized by Invitrogen (Shanghai, China). Some biochemical indexes, such as fasting plasma-glucose, triglycerides and total cholesterol were also measured.

**Measurement of Serum MBL Levels**

MBL concentrations were measured with enzyme-linked immune-sorbent assay (ELISA) (human MBL DuoSet, RD Systems). To guarantee the credibility and accuracy of the data of the assay, a spike and recovery immunoassay sample validation protocol was applied. High quality Bovine Serum Albumin (BSA, Sigma, USA) and 10% fetal calf serum (USA) were used as reagent diluents. The protocol showed that the spike recovery rate was in the range of 90%–120% and the sample exhibited good linear dilution, which indicated that no component in the samples interfered in ELISA. The serum concentrations of MBL were from the 675 patients.

**Statistical Methods**

Allele and genotype frequency distributions for rs1800450 and rs11003125 were compared between controls and patients as well as patients grouped according to nephropathy status. Linkage disequilibrium and haplotype analyses were performed with Haplovie 4.2. Odds ratio with a 95% confidential interval (CI) were calculated with SHesis software (http://analysis2.bio-x.cn/myAnalysis.php) [18]. Data were expressed as means and standard deviations (SD) for normally distributed variables, or medians and interquartile ranges (IQRs) for non-normally distributed variables. Between-group comparisons were performed with the $X^2$ test for categorical variables and the $T$ test or Wilcoxon signed rank test for continuous variables. $P < 0.05$ was considered to be statistically significant. All analyses were performed using SAS 9.1 (SAS institute Inc., Cary, NC).

**Results**

Clinical characteristics of the study subjects are shown in Table 1. There was no gender difference between patients and controls ($P=0.13$). Compared with controls, patients with type 2 diabetes had a significantly higher body mass index (BMI), waist-to-hip ratio (WHR), systolic blood pressure (SBP), triglyceride (TG), total cholesterol (TG), fasting plasma glucose (FPG), and creatinine (Cr) ($P<0.001$). Age, smoking status, and drinking status were also statistically significant between patients and controls. The clinical indexes were not significantly different among the three groups classified by nephropathy status except for gender, SBP, DBP, TC, Cr, and BUN.

**MBL2 Gene with type 2 Diabetes and Diabetic Nephropathy**

No mutation was found for rs1800451 in our study, which is consistent with previously published studies conducted in the Chinese population [16,17]. The rs1800450 and rs11003125 were in Hardy-Weinberg equilibrium both in control subjects and patients with type 2 diabetes (Table 2). The rs1800450 and rs11003125 SNPs had strong linkage disequilibrium ($r^2 = 0.97$) in our population and made up haplotype block 1 (Fig. 1).

The only haplotypes constructed from the risk-conferring (GC) allele showed increased trends for type 2 diabetes ($OR = 1.2$, 95% CI $1.1–1.4$, $P=0.01$, Table 3). For rs1800450 (Table 4), the GG genotype frequency was 74.4% in patients with type 2 diabetes vs. 68.8% in controls ($P = 0.02$), while the GA genotype frequency was

---

**Table 2. Hardy-Weinberger Equilibrium.**

| Polymorphism      | Genotype | Patients | $P$   | Controls | $P$ |
|-------------------|----------|----------|-------|----------|-----|
| Rs1800450         | GG       | 502      |       | 588      |     |
|                   | GA       | 155      |       | 250      |     |
|                   | AA       | 18       | 0.155 | 17       | 0.104 |
| Rs11003125        | GC       | 350      |       | 411      |     |
|                   | GG       | 122      |       | 213      |     |
|                   | CC       | 203      | 0.175 | 231      | 0.264 |

---

Figure 1. The LD displays plot of rs1800450 and rs11003125.

doi:10.1371/journal.pone.0083059.g001
22.9% in patients with type 2 diabetes vs. 29.2% in controls ($P=0.01$). For rs11003125, the GC genotype frequency was 18.07% in patients with type 2 diabetes vs. 24.91% in controls ($P=0.01$). The distributions of allele frequencies of rs1800450 and rs11003125 did not produce a statistical difference between patients and controls ($P=0.06, 0.84$, respectively).

The distributions of genotypes and allele frequencies among patients with normal UAE, microalbuminuria, and macroalbuminuria are shown in Table 4. GA and AA genotype frequencies of rs1800450 were significantly different between patients with normal UAE and microalbuminuria, as well as for G and A alleles. No difference was found for rs11003125. Compared with other genotypes, subjects with the GG genotype of rs1800450 and the (GC+CC) genotype of rs11003125 had higher biochemical indexes, such as BMI, WHR, SBP, FPG, TC and TG and Cr, but no significant $p$ value was found after adjustment for age, gender, smoking status and drinking status (Table S2).

**MBL2 Gene and Serum MBL Levels**

For rs1800450 (Fig. 2), compared with subjects with GA and AA genotypes (median serum MBL: 621 ng/ml and 661 ng/ml), subjects with the GG genotype had much higher serum MBL levels (median: 1322 ng/ml). For rs11003125 (Fig. 3), compared with subjects with the GG genotype, subjects with the CC genotype had much higher serum MBL levels (median serum MBL: 1553 ng/ml vs. 690 ng/ml).

**Table 3. Haplotype analyses of rs180045 and rs11003125.**

| Haplotype     | Rs1800450 | Rs11003125 | Frequency | OR(95% CI) | P |
|---------------|-----------|------------|-----------|------------|---|
| Cases (G)     | 0.559     | 0.510      | 1.2(1.1-1.4) | 0.01       |
| Controls (G)  | 0.300     | 0.324      | 0.9(0.8-1.0) | 0.15       |
| A             |           |            | 0.140     | 0.165      | 0.8(0.7-1.0) | 0.06 |

**Table 4. The distribution of genotype and allele frequency of MBL2 in the study population.**

| Polymorphisms | Type 2 diabetes | Controls | $P$ | Type 2 diabetes | $P$ |
|---------------|----------------|----------|-----|----------------|-----|
| N             | 675            | 855      | –   | 260            | 378 | 37 | – |
| Rs1800450     |               |          |     |               |     |
| GG            | 502(74.4)      | 588(68.8)| 0.02| 185(71.2)      | 289(76.4)| 28(75.7)| 0.32 |
| GA            | 155(22.9)      | 250(29.2)| 0.01| 61(23.5)       | 64(22.8)* | 8(21.6) | 0.96 |
| AA            | 18(2.7)        | 17(2.0)  | 0.38| 14(5.3)        | 3(0.8)* | 1(2.7)  | 0.01 |
| G             | 1159(85.9)     | 1426(83.4)| –  | 431(82.9)      | 664(87.8)* | 64(86.5) | – |
| A             | 191(14.1)      | 284(16.6)| 0.06| 89(17.1)       | 92(12.2) | 10(13.5)| 0.04 |
| Rs11003125    |               |          |     |               |     |
| GG            | 350(51.9)      | 411(48.1)| 0.14| 52(20.0)       | 65(17.2) | 5(13.5) | 0.51 |
| GC            | 122(18.1)      | 213(24.9)| 0.01| 131(50.4)      | 198(52.4) | 21(56.8) | 0.73 |
| CC            | 203(30.0)      | 231(27.0)| 0.19| 77(29.6)       | 115(30.4) | 11(29.7) | 0.98 |
| G             | 822(60.9)      | 1035(60.5)| –  | 235(45.2)      | 328(43.4) | 31(41.9) | – |
| C             | 528(39.1)      | 675(39.5)| 0.84| 285(54.8)      | 428(56.6) | 43(58.1) | 0.76 |

*P<0.05 between patients with microalbuminuria and normal UAE.*

doi:10.1371/journal.pone.0083059.t004

**Discussion**

**MBL2 Gene and Type 2 Diabetes**

Epidemiological studies have suggested that genetically determined variation in MBL levels influences the susceptibility and the course of different types of infectious, autoimmune, metabolic and cardiovascular diseases [19–22]. Most studies focused on the association of the MBL2 gene with type 1 diabetes and the conclusions were controversial [2,23,24]. Few studies have discussed the association between the MBL2 gene and type 2 diabetes. A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI 2) trial suggested that the distributions of MBL2 genotypes were similar to those known in the general population [25]. Because the results were blunted by traditional risk factors, the report did not resolve the issues of whether low or high serum MBL levels and which genotypes were harmful to patients with type 2 diabetes and myocardial infarction. Muller’s study showed that the association between genes and diabetes was restricted to the region in the MBL2 gene, which means that evidence of association with type 2 diabetes is more likely to be derived from the MBL2 gene rather than from other genes. Their result demonstrated that in both Native Americans (number = 3723) and Old Order Amish (number = 486), the rs1800450 and rs11003125 SNPs (from nineteen tag SNPs of MBL2 gene) contributed to type 2 diabetes susceptibility [11]. We also found that rs1800450 and rs11003125 were associated with type 2 diabetes. Compared with controls, the GG genotype and G allele of rs1800450 were more common in patients with type 2 diabetes, while the GA genotype and A allele frequencies were higher in controls. Haplotype analysis showed...
Figure 2. Distribution of serum MBL concentrations in type 2 diabetes stratified by rs1800450 genotypes. Black horizontal lines are median values; □ are interquartile ranges; ○ are outliers; * are extreme values. P values were results of pairwise comparison. The median MBL of the GA genotype was 621 ng/mL (IQR: 419–847), the median MBL of the GG genotype was 1322 ng/mL (IQR: 873–1823), and the median MBL of the AA genotype was 661 ng/mL (IQR: 488–1521).

doi:10.1371/journal.pone.0083059.g002

Figure 3. Distribution of serum MBL concentrations in type 2 diabetes stratified by rs11003125 genotypes. Black horizontal lines are median values; □ are interquartile ranges; ○ are outliers; * are extreme values. P values were results of pairwise comparison. The median MBL of the GC genotype was 962 ng/mL (IQR: 631–1498), the median MBL of the GG genotype was 690 ng/mL (IQR: 446–1181), and the median MBL of the AA genotype was 1553 ng/mL (IQR: 1130–2073).

doi:10.1371/journal.pone.0083059.g003
that subjects with the G allele of rs1800450 and C allele of rs11003125 had a 20% higher risk for type 2 diabetes. This evidence suggested that the GG genotype of rs1800450 may be harmful to patients with type 2 diabetes and the variation of rs1800450 (G→A) may be beneficial for individuals in reducing the risk of type 2 diabetes. Because rs11003125 is in high LD with other SNPs (within intro 2 and a flanking region of MBL2 gene), the contribution of other functional SNPs cannot be ignored. Our study did not indicate whether the MBL2 gene influences type 2 diabetes by affecting insulin secretion or insulin action. Additional studies are needed to investigate the impact of the MBL2 gene on specific type 2 diabetes related pathways. The possible explanation of the contradictory results between the MBL2 gene and diabetes may be that the variants of the MBL2 gene have significant racial differences and only a few polymorphisms have been studied in relatively small samples.

MBL2 Gene and Diabetic Nephropathy

This study is the first study to examine the associations of the MBL2 gene and type 2 diabetic nephropathy. In Kaunisto’s study, significant evidence of association was observed for rs920727 with patients with end-stage renal disease (ESRD) and normal UAE. However, after adjustment for the potential confounders no evidence of the association was observed [2]. In Hansen’s study, high MBL genotypes were significantly more frequent in diabetic patients with nephropathy than those with normal UAE, and the risk of having nephropathy given a high MBL genotype assessed by odds ratio (OR) was 1.52 [7]. In our study, GA and AA genotypes and allele frequencies of rs1800450 were statistically significant between patients with normal UAE and microalbuminuria, but the evidence was not strong enough to reach the conclusion that rs1800450 was associated with type 2 diabetic nephropathy. No evidence was found for rs11003125.

MBL and Diabetic Nephropathy

In Hansen’s study, frequencies of the genotypes producing high serum MBL levels were more common in patients with diabetic nephropathy than patients with normal albuminuria [7], which suggested that serum MBL levels may be involved in the pathogenesis of micro- and macrovascular complications. After following up 326 patients with type 2 diabetes for 15 years, Hansen found that measurement of serum MBL alone can provide prognostic information on mortality and the development of albuminuria [26]. A recent study has proved that elevated serum MBL in patients with type 2 diabetes indicates poor diabetic control and development of diabetic nephropathy, especially in combination with serum CRP [27]. The association between high serum MBL levels and diabetic nephropathy was also observed in the present study, which is in accordance with previous studies [2,7,8]. Type 1 and type 2 diabetes are different, but the association between serum MBL levels and diabetic nephropathy is consistent with previous studies suggesting that diabetic microvascular lesions may have a similar pathogenesis, regardless of type 1 diabetes or type 2 diabetes. Although the physiological mechanisms underlying the association of serum MBL levels with diabetic nephropathy are still unknown, it was previously shown that serum MBL plays a dual role in modifying inflammatory responses [11]. Deficiency of serum MBL has been linked to insulin resistance and obesity as a result of a chronic infectious state or low-grade inflammation [28]. Serum MBL levels also affect metabolic pathways through stimulating fatty acid oxidation in skeletal muscle, or reducing release of tumor necrosis factor-α, interleukin-1, and interleukin-6 [29,30]. On the other hand, high
levels of serum MBL could lead to an overly activated complement system inducing inflammation damage or interweaving a complex autoimmune process [19].

**MBL2 Gene and MBL Concentrations**

Although serum MBL levels may increase two- to threefold during acute phase response, the serum MBL levels remain genetically determined [9]. Both rs1800450 and rs11003125 of the MBL2 gene showed strong associations with serum MBL levels in our study, which was consistent with previous studies [2,7]. Subjects with the CC genotype of rs1800450 and the GC genotype of rs11003125 had much higher serum MBL levels than those with GA and AA genotypes. In addition, high levels of serum MBL were associated with diabetic nephropathy. This evidence proved the association of MBL2 gene with type 2 diabetes from another aspect. Some variants may have an independent effect on serum MBL levels or tag other still unknown functional variants, so more SNPs of the MBL2 gene are needed to better understand the association between the MBL2 gene and serum MBL levels.

Our study had some limitations. First, we did not collect the medication history of oral hypoglycemic drugs in our questionnaire, which may influence the levels of serum MBL. Second, because only three SNPs of the MBL2 gene were selected, the associations between the seven MBL2 haplotypes and type 2 diabetes and diabetic nephropathy were not discussed.

In summary, rs1800450 and rs11003125 of the MBL2 gene are associated with type 2 diabetes in the Chinese Han population, but not associated with diabetic nephropathy. The two SNPs have a strong impact on serum MBL levels, and serum MBL levels which may influence diabetic nephropathy.

**References**

1. Yang W, Lu J, Weng J, Jin W, Ji L, et al. (2010) Prevalence of diabetes among rural and urban Chinese. N Engl J Med 362: 1090–1101.
2. Kaunisto MA, Spolink L, Sallinen R, Pettersson-Fernholm K, Sarzheiro M, et al. (2009) Elevated MBL Concentrations Are Not an Indication of Association Between the MBL2 Gene and Type 1 Diabetes or Diabetic Nephropathy. Diabetes 58: 1710–1714.
3. Bouman NH, Eerlikh P, Terpstra OT, Daha MR, de Knijff P, et al. (2005) Elevated levels of mannmannose-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes 54: 3002–3006.
4. Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, et al. (2003) Elevated levels of mannmann-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 88: 4857–4861.
5. Sarzheiro M, Am T, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade infection in type 1 diabetic patients. Diabetologia 46: 1402–1407.
6. Dommert RM, Klein N, Turner MW (2006) Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 68: 193–209.
7. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stoebouwer CD, et al. (2004) Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 53: 1570–1576.
8. Sarzheiro M, Forsblom C, Hansen TK, Teppo AM, Fagerudd J, et al. (2005) Increased levels of mannmann-binding lectin in type 1 diabetic patients with insulin and overt hepatic nephropathy. Diabology 46: 198–202.
9. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van der Berghe G (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88: 1082–1086.
10. Steffensen R, Thiel S, Varming K, Jeruld C, Jensenius JC (2000) Detection of structural gene mutations and promoter polymorphisms in the mannann-binding lectin (MBL) gene by polymerase chain reaction with sequence specific primers. J Immunol Methods 241: 33–42.
11. Muller YL, Hansen RL, Bia L, Mack J, Shi X, et al. (2010) Functional variants in MBL2 are associated with type 2 diabetes and pre-diabetes traits in Pima Indians and the old order Amish. Diabetes 59: 2080–2085.
12. American Diabetes Association (2003) Clinical practice recommendations 2001: diabetic nephropathy. Diabetes Care 24 (suppl. 8): S69–72.
13. Viberti GC, Mogensen CE, Group LC, Pauls JF (1994) Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 273: 273–279.
14. Parving HH, Lehnert H, Brichason-Mortensen J, Gomis R, Andersen S, et al. (2001) The Effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–876.
15. Garred P, Larsen F, Sefjvarth J, Fugiga R, Madsen HO (2006) Mannose-binding lectin and its genetic variants. Genes Immun 7: 83–94.
16. Shi H, Wang F, Jin L, Liu M, Hong W, et al. (2001) Genotype polymorphism and its implications of mannose-binding protein allele in 5 Chinese nationalities. Chin J Med Genet 18: 202–205.
17. Gu X, Guo X, Wang W, Huang Y, Wu X (2005) The study on the relationship between genotype polymorphism of mannose-bonding lectin and susceptibility to coronary arterydisease in the subjects of Han nationality of Hubei province. J Clin Cardiol 21: 423–426.
18. Shi YY, He L (2005) SHEats, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97–98.
19. Turner MW, Hannas RM (2000) Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenetics 2: 305–322.
20. Kilpatrick DC (2002) Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 1572: 401–413.
21. Eiken DP, Minchinton RM (2003) Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 37: 1496–1505.
22. Noytink L, Shapiro F (2004) Mannose-binding lectin: the stepping stones from clinical research to personalized medicine. Personalized Med 1: 55–52.
23. Araujo J, Brandao LA, Guimaraes RL, Santos S, Falcao EA, et al. (2007) Mannose-binding lectin gene polymorphisms are associated with type 1 diabetes in Brazilian children and adolescents. Hum Immunol 68: 739–743.
24. Tutsunii A, Ikeyama H, Takahashi R, Murata H, Goto D, et al. (2003) Mannose binding lectin gene polymorphism in patients with type 1 diabetes. Hum Immunol 64: 621–624.
25. Mellbin LG, Hamsten A, Malmberg K, Schifens R, Ryden L, et al. (2010) Mannose-bing lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33: 2451–2456.
26. Hansen TK, Gall MA, Tarnow L, Thiel S, Stoebouwer CD, et al. (2006) Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 166: 2007–2013.
27. Elawa G, Hamsten A, Mellbin LG, Schifens R, Ryden L, et al. (2010) Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 33: 2451–2456.
28. Fuchs D, Selby R, Ricotta R, Erickson MR, et al. (2001) Proteolytic cleavage product, of 30-kDa adipocyte complement-related protein is associated with progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 273: 273–279.
29. Parving HH, Lehnert H, Brichason-Mortensen J, Gomis R, Andersen S, et al. (2001) The Effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–876.
30. Selad L, Mikkilä V, Hirvijä K, Sipponen P, Hakkarainen T, et al. (1995) Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannose binding protein inhibits TNF-alpha release. J Immunol 154: 851–860.